Skip to main content

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

The Original Article was published on 16 July 2018

Correction to: J Exp Clin Cancer Res 37, 153 (2018)

https://doi.org/10.1186/s13046-018-0810-7

Following publication of the original article [1], the authors identified a minor error in Fig. 4; specifically:

  • Fig. 4 b: Incorrect flow cytometry graphs of VEL (20uM) and SA + VEL were used; the figure has been corrected to use the correct graphs

Fig. 4
figure 1

Co-administration of SAHA and veliparib enhanced PCa cell apoptosis. PCa cells LNCaP, C4–2 and PC-3 were treated with SAHA and veliparib alone or in combination at the indicated doses for 4 days (a LNCaP. b C4–2. c PC-3. d VCap, CWR22Rv1, DU145). Cells were stained with FITC-Annexin V antibody and counterstained with PI. The apoptotic cells were analyzed by flow cytometery. Representative dot plots of FITC-Annexin V/PI staining are shown. Graph shows mean apoptotic cells (Annexin-V+/PI+) ± SD. Experiments were performed in triplicate. Cell apoptosis was validated by testing the protein levels of cleaved PARP by western blotting (a-d). *p < 0.05; ** p < 0.01 (SAHA or Veliparib alone vs. co-treatment)

The corrected figure is given here. The correction does not have any effect on the final conclusions of the paper.

Reference

  1. Yin L, Liu Y, Peng Y, et al. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res. 2018;37:153. https://doi.org/10.1186/s13046-018-0810-7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Xiong Li.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yin, L., Liu, Y., Peng, Y. et al. Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res 41, 72 (2022). https://doi.org/10.1186/s13046-022-02290-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13046-022-02290-9